Envista (NYSE:NVST) Price Target Raised to $19.00

Envista (NYSE:NVST) had its price objective raised by Piper Sandler from $17.00 to $19.00 in a report released on Friday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

Other research analysts have also issued reports about the stock. Bank of America dropped their price objective on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. UBS Group lifted their target price on shares of Envista from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, July 29th. Evercore ISI lifted their target price on shares of Envista from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. Robert W. Baird raised shares of Envista from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $21.00 to $23.00 in a report on Tuesday, May 27th. Finally, Morgan Stanley set a $16.00 price objective on shares of Envista in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.92.

Envista Price Performance

Shares of NVST opened at $20.78 on Friday. The firm’s fifty day simple moving average is $19.41 and its 200-day simple moving average is $18.60. Envista has a twelve month low of $14.22 and a twelve month high of $23.00. The company has a current ratio of 2.44, a quick ratio of 2.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of 64.94, a PEG ratio of 1.22 and a beta of 1.00.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.84%. The firm had revenue of $682.10 million for the quarter, compared to analyst estimates of $638.21 million. During the same period last year, the business earned $0.11 EPS. Envista’s revenue for the quarter was up 7.7% compared to the same quarter last year. Equities analysts forecast that Envista will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of Envista by 1,338.3% during the 1st quarter. GAMMA Investing LLC now owns 33,139 shares of the company’s stock worth $572,000 after buying an additional 30,835 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Envista by 66.6% in the fourth quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock worth $922,000 after acquiring an additional 19,100 shares in the last quarter. Comerica Bank increased its position in shares of Envista by 8.2% in the fourth quarter. Comerica Bank now owns 121,851 shares of the company’s stock worth $2,350,000 after acquiring an additional 9,248 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Envista by 220.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 47,319 shares of the company’s stock worth $817,000 after acquiring an additional 32,556 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Envista in the fourth quarter worth $38,052,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.